Pfizer subsidiary Parke-Davis, introduced Neurontin in 1993 as a new treatment for a range of conditions including epilepsy and neuropathic pain. Neurontin is the brand name of the drug Gabapentin and as the name indicates, it is similar in structure to GABA although it has not been shown to bind to actual GABA receptors in the body. However, Neurontin does modulate two enzymes which are involved in the biosynthesis of GABA such that indirectly, Neurontin leads to an increase in GABA levels.
Neurontin was initially introduced to help deal with neuropathic pain and seizures, with the former not being well handled by existing painkilling medications at the time.
Since its introduction, Neurontin has shown efficacy in a number of other use cases with it being used to treat anxiety, bipolar disorder and insomnia although others have raised concern that it is not suitable as a treatment for these conditions.
Neurontin is a much more targeted solution to neuropathic pain compared to traditional painkillers such as NSAID's or opiod based medication and does not have the range of side effects associated with the latter. Indeed, Neurontin has been recommended as a first line treatment in Europe for dealing with diabetic neuropathy and posttherpetic neuropathy to name just two conditions.
Neurontin has been prescribed to a diverse group of individuals experiencing a wide range of conditions although it should be considered a primary treatment choice only in those with neuropathic pain. Neurontin has been prescribed for both men and women.
The dosage used of Neurontin as well as how long it is used for is strictly based on the advice of a medical professional but the drug itself has been used over extended periods of time with success. Always refer to product literature.